SCHEMBL4237495

SCHEMBL4237495

CCN(CC(F)(F)F)C1CC1

nearest known ligand 0.36

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.36
SLC6A4 P31645 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18475075 0.86 SLC6A2 (0.51) SLC6A2SLC6A4
Hydrochloric Acid SCHEMBL18428966 0.84 SLC6A2 (0.50) SLC6A2SLC6A4
SCHEMBL18469960 0.84 NOS3 (0.35) SLC6A2SLC6A4
SCHEMBL22989499 0.80 SLC6A2 (0.33) SLC6A2SLC6A4
SCHEMBL9284811 0.78 SLC6A2 (0.35) SLC6A2SLC6A4
SCHEMBL18440487 0.77 ACKR3 (0.38) SLC6A2SLC6A4
SCHEMBL835196 0.76
SCHEMBL9862148 0.76 ADH1C (0.33) SLC6A2SLC6A4
SCHEMBL9278394 0.71 ADH1C (0.34) SLC6A2SLC6A4
SCHEMBL24120114 0.71 SLC6A2 (0.39) SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-10-23 US disclosed
US-8741912-B2 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED (US) 2014-06-03 US disclosed
US-20120316186-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED 2012-12-13 US disclosed
US-20090088445-A1 Deazapurines useful as inhibitors of Janus kinases VERTEX PHARMACEUTICALS INCORPORATED 2009-04-02 US disclosed
EP-2001884-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES Vertex Pharmaceuticals, Inc. (US) 2008-12-17 EP disclosed
WO-2007117494-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES VERTEX PHARMACEUTICALS INCORPORATED (US) 2007-10-18 WO disclosed
CN-1499972-A Imidazolyl derivatives as corticotropin releasing factor inhibitors ����˹�ж�-����˹˹������˾ 2004-05-26 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090088445-A1 Deazapurines useful as inhibitors of Janus kinases JAK1, JAK3, JAK2 SLC6A2 4449/4885SLC6A4 4548/4885
US-20140315931-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 SLC6A2 4449/4885SLC6A4 4548/4885
US-20120316186-A1 DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES JAK1, JAK3, JAK2 SLC6A2 4449/4885SLC6A4 4548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.